Restructuring program targets £600M annual savings. Can BATS extend gains?

Traders Union
All News
Financial News
British American Tobacco jumps 3% today

Highlights

British American Tobacco is supporting its share price through an extended buyback program executed by UBS AG London until July 29.
The company's Fit2Win restructuring aims for £600 million in annual savings by 2028, targeting improved long-term operating margins.
Technical signals remain strongly bullish, with price expected to trade within the GBX4,507–4,770 range and immediate support at GBX4,496.

Share buybacks boost support as Fit2Win restructuring promises margin gains

British American Tobacco has extended its share buyback program, with UBS AG London actively executing repurchases between June 30 and July 29, according to Stockstotrade. This direct reduction in free float is providing mechanical support for the stock, as ongoing purchases drive liquidity and can support upward price action. In addition, the company reaffirmed the progress of its Fit2Win restructuring program—expected to achieve £600 million in annual savings by 2028 and affecting approximately 9,000 roles globally—offering longer-term margin improvement potential as also reported by Stockstotrade.

Overbought signals persist as bullish momentum outpaces reversal risks

On the technical front, BATS is trading above the MA-20 at GBX4,410 and MA-50 at GBX4,421 on the hourly chart, as well as above the MA-200 at GBX4,329 on the daily chart. Immediate support is marked by the Ichimoku Kijun level at GBX4,496. Momentum indicators remain strong: Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both signal a Buy, with the Relative Strength Index (RSI) at 84.59 indicating overbought conditions. Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power also indicate overbought territory, while the Awesome Oscillator continues to support the prevailing upward trend. Notably, although multiple oscillators signal overbought conditions, no reversal has been triggered, but the divergence between persistent overbought readings and sustained momentum should be monitored.

Range consolidation likely as bullish momentum outweighs reversal threats

Over the coming days, BATS is expected to consolidate within a broad range from GBX4,507 to GBX4,770, consistent with typical volatility bands relative to current levels. Continued upside movement is highly probable, with only a limited chance of a downside reversal in the near term. The baseline scenario anticipates price action stabilizing within this corridor, though an acceleration in bullish momentum could result in a breakout above resistance. Conversely, if sellers step in and the price drops below immediate support at the Kijun level, a pullback toward the lower bound of the projected range may unfold.

Anton Kharitonov, expert at Traders Union, sees British American Tobacco supported by active share buybacks and restructuring progress, but remains cautious about the sustainability of the recent rally. He notes that technical momentum and key moving averages favor the bulls, yet many oscillators flag overbought conditions that could soon cap gains. Base case is for GBX4,507–4,770 consolidation, with risk of pullback if immediate support breaks. "Despite positive catalysts, I remain defensive here until overbought signals clear or support at the Kijun level holds convincingly."

Earlier, analysts noted that British American Tobacco maintained a robust bullish technical structure, although they cautioned that mixed momentum signals could result in a period of consolidation. With the extension of the share buyback program now providing an additional catalyst alongside strong technical momentum, the key risk for traders is a potential acceleration above resistance if current support levels hold.

Source of Data: BATS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.